OPTISON (Perflutren Protein-Type A Microspheres Injectable Suspension, USP) is a sterile non-pyrogenic suspension of microspheres of human serum albumin with perflutren for contrast enhancement during the indicated ultrasound imaging procedures. The vial contains a clear liquid lower layer and a white upper layer that, after resuspension by gentle mixing, provides a homogeneous, opaque, milky-white suspension for intravenous injection.
OPTISON is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricle and to improve the delineation of the left ventricular endocardial borders.
Media Articles Related to Optison (Albumin Human)
FDA approves new diagnostic imaging agent to detect recurrent prostate cancer
Source: Prostate / Prostate Cancer News From Medical News Today [2016.05.31]
The U.S. Food and Drug Administration has approved Axumin, a radioactive diagnostic agent for injection.
Flexible future of point-of-care disease diagnostic
Source: Bird Flu / Avian Flu News From Medical News Today [2015.07.29]
The world-wide deployment of biomedical devices for health monitoring, point-of-care diagnostics and environmental sensing is hampered by their high cost that is not readily affordable for e.g.
Adverse outcomes not improved in novel screen-and-treat program for malaria in pregnancy
Source: Infectious Diseases / Bacteria / Viruses News From Medical News Today [2016.09.14]
A novel strategy to screen pregnant women for malaria with rapid diagnostic tests and treat the test-positive women with effective antimalarials does not lower the risk of adverse pregnancy...
Fecal Hb and Calprotectin As Indicators of Bowel Disease
Source: Medscape General Surgery Headlines [2016.09.13]
This study assessed the diagnostic accuracy of quantitative fecal Hb and fecal calprotectin tests in patients presenting to primary care with bowel symptoms.
Underutilization of CAD Testing in New-Onset Heart Failure
Source: Medscape Radiology Headlines [2016.09.13]
Are patients hospitalized with new-onset heart failure receiving appropriate and timely diagnostic testing for ischemic coronary artery disease, as guidelines recommend?
Journal of the American College of Cardiology
Published Studies Related to Optison (Albumin Human)
Glycated albumin predicts the effect of dual and single antiplatelet therapy on
recurrent stroke. 
recurrence of stroke in patients on either dual or single antiplatelet therapy... CONCLUSIONS: GA could be a potential biomarker to predict the effects of dual and
Effects of combined lipoic acid and pyridoxine on albuminuria, advanced glycation
end-products, and blood pressure in diabetic nephropathy. 
This study was designed to investigate the effects of combined administration of
lipoic acid and pyridoxine on albuminuria, oxidative stress, blood pressure,
serum advanced glycation end-products, nitric oxide (NO), and endothelin-1 in
patients with diabetic nephropathy.
High-dose albumin treatment for acute ischaemic stroke (ALIAS) Part 2: a
randomised, double-blind, phase 3, placebo-controlled trial. 
proportion of patients with a favourable outcome... INTERPRETATION: Our findings show no clinical benefit of 25% albumin in patients
Albumin resuscitation for traumatic brain injury: is intracranial hypertension
the cause of increased mortality? 
Mortality is higher in patients with traumatic brain injury (TBI) resuscitated
with albumin compared with saline, but the mechanism for increased mortality is
Associations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study. [2011.07]
CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatinine ratio is independently associated with HbA1c and NT-proBNP, even in non-diabetic patients.
Clinical Trials Related to Optison (Albumin Human)
CeVUS With Intravesical Administration of OPTISON TM (Trademark) in Children [Recruiting]
In this clinical trial the investigators aim to evaluate the diagnostic feasibility and
safety of ceVUS with the intravesical use of OPTISON for vesicoureteral reflux detection and
urethral imaging in children.
A Prospective Surveillance Trial to Evaluate the Safety of Optison in Clinical Practice. [Completed]
This prospective surveillance trial will gather safety information for Optison when it is
used in routine practice.
Regadenoson Real Time Perfusion Imaging Trial-Optison [Recruiting]
The purpose if this study is to examine how effective Regadenoson is in detecting coronary
artery disease during a stress echocardiogram when Optison is administered. Optison is a
contrast agent that improves the images of the heart on the echocardiogram (echo) machine.
Optison is approved by the Food and Drug Administration (FDA) to use during stress
echocardiograms. Regadenoson is a commercially available rapid acting stress agent that is
used to chemically increase the heart rate and is approved for nuclear imaging tests.
Regadenoson is a FDA approved drug but not for the intended use in this study.
Dose-Finding, Feasibility Study of Optison in Contrast Enhanced U/S for the Detection of Carotid Artery Disease [Terminated]
The purpose of this study is to find the optimal dose from 3 different dose levels - 0. 15
mL, 0. 5 mL and 1. 5 mL of Optison in assessing the presence of disease of the carotid
arteries when comparing pre-contrast to post-contrast ultrasound (U/S) by dose group.
Evaluate Effect of Optison on Pulmonary Artery Systolic Pressure (PASP) and Pulmonary Vascular Resistance (PVR). [Completed]